otamixaban

Otamixaban is a synthetic, parenteral, small molecule anticoagulant that acts as a potent, selective, rapid acting, competitive and reversible direct inhibitor of coagulation factor Xa (FXa). It was developed by Sanofi-Aventis for the management of acute coronary syndrome. Otamixaban inhibits both free and prothrombinase-bound factor Xa, thereby blocking the conversion of prothrombin to thrombin in the coagulation cascade. This mechanism reduces thrombus formation and has been shown to be effective in preclinical models and clinical trials for reducing cardiovascular events such as myocardial infarction. Otamixaban has a short half-life (1.5–3 hours) and is administered intravenously. Despite promising early results, its development was discontinued after phase III trials failed to show superior efficacy compared to standard therapy with unfractionated heparin[1][2][3][4][5].

Other names

otamixaban hydrochloride